|

Lactulose 667 milligram/milliliter Oral Solution Clinical Trials

1 actively recruiting trial

Also known as: Lactulose syrup

Pipeline

Phase 4: 1

Top Sponsors

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1

Indications

  • Pathological Processes1
  • Liver Disease1
  • Hepatic Encephalopathy1
  • Portal Hypertension1
  • Cirrhosis, Liver1

Other1 trial

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.